Dong GF, Sun YQ, Li C, Xie SS. Efficacy of pegylated interferon α-2b in treatment of chronic hepatitis B.
Shijie Huaren Xiaohua Zazhi 2014;
22:1569-1573. [DOI:
10.11569/wcjd.v22.i11.1569]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the efficacy of pegylated interferon α-2b (PEG-IFN α-2b) in the treatment of chronic hepatitis B (CHB).
METHODS: Sixty hospitalized patients with CHB who were treated with PEG-IFN α-2b from June 2012 to June 2013 were included in this study. Changes in tumor necrosis factor-α (TNF-α), γ interferon (IFN-γ), interleukin-6 (IL-6), IL-8 and IL-10 were observed between before and after treatment. HBeAg/HBeAb status and HBV DNA levels were detected 3, 6 and 9 mo after treatment.
RESULTS: After treatment, TNF-α, IFN-γ, IL-6, IL-8 and IL-10 showed significant changes compared with pretreatment data (P < 0.05). Three months after treatment, ALT normalization was achieved in 11 (18.33%) cases, negative conversion of HBeAg in 7 (11.66%) cases, and negative conversion of HBV DNA in 15 (25.00%) cases. Six months after treatment, ALT normalization was achieved in 32 (53.33%) cases, negative conversion of HBeAg in 20 (33.33%) cases, and negative conversion of HBV DNA in 26 (43.33%) cases. Nine months after treatment, ALT normalization was achieved in 46 (76.6%) cases, negative conversion of HBeAg in 37 (61.6%) cases, and negative conversion of HBV DNA in 37 (61.6%) cases. The rates of liver function recovery, HBeAg seroconversion and negative conversion of HBV DNA were significantly different between before and 3, 6 and 9 mo after treatment (P < 0.05).
CONCLUSION: PEG-IFN α-2b is effective in the treatment of CHB.
Collapse